This study aimed to evaluate the safety and efficacy of humanized CD19-targeted chimeric antigen receptor T-cell(CAR-T)in patients with relapsed/refractory acute B cell lymphoblastic leukemia(R/R B-ALL). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.